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B cells from HIV-infected patients with primary central nervous
system lymphoma display an activated phenotype and have a
blunted TNF-α response to TLR9 triggering
Abstract
Each cell in HIV-associated primary central nervous system lymphoma (PCNSL) harbors latent EBV.
Notably, the triggering of TLR9, a key event in HIV pathogenesis, also promotes EBV latency and
transformation. We hypothesized that because only a minority of HIV-infected patients develops
PCNSL, their B cells exhibit aberrant signaling responses to TLR9 triggering. We found higher levels of
IL-6, CD80, and CD86 expression at baseline in B cells of those patients than in B cells of matched
controls, whereas TNF-a expression was lower. Notably, on TLR9 triggering with CpG 2006, CD80 and
TNF-α were up-regulated to a lesser extent in B cells of the former than in those of matched controls.
The reduced up-regulation of CD80 might be explained by its higher baseline expression resulting in a
more blunted response rather than a specific deficit of the signaling response to TLR9 triggering.
However, this cannot explain the blunted TNF-α response, which warrants further investigation. Finally,
since increased IL-6 expression is linked to EBV-associated Hodgkin's lymphoma, the enhanced
baseline expression of IL-6 might be important in the pathogenesis of PCNSL in HIV-infected patients.
Short Communication: B Cells from HIV-Infected Patients
with Primary Central Nervous System Lymphoma Display
an Activated Phenotype and Have a Blunted
TNF-a Response to TLR9 Triggering
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Abstract
Each cell in HIV-associated primary central nervous system lymphoma (PCNSL) harbors latent EBV. Notably,
the triggering of TLR9, a key event in HIV pathogenesis, also promotes EBV latency and transformation. We
hypothesized that because only a minority of HIV-infected patients develops PCNSL, their B cells exhibit
aberrant signaling responses to TLR9 triggering. We found higher levels of IL-6, CD80, and CD86 expression at
baseline in B cells of those patients than in B cells of matched controls, whereas TNF-a expression was lower.
Notably, on TLR9 triggering with CpG 2006, CD80 and TNF-a were up-regulated to a lesser extent in B cells of
the former than in those of matched controls. The reduced up-regulation of CD80 might be explained by its
higher baseline expression resulting in a more blunted response rather than a specific deficit of the signaling
response to TLR9 triggering. However, this cannot explain the blunted TNF-a response, which warrants further
investigation. Finally, since increased IL-6 expression is linked to EBV-associated Hodgkin’s lymphoma, the
enhanced baseline expression of IL-6 might be important in the pathogenesis of PCNSL in HIV-infected patients.
Primary central nervous system lymphoma (PCNSL) isa large B cell lymphoma of the immunoblastic type.1 It
mostly occurs in patients infected with human immunodefi-
ciency virus (HIV) type 1 when the CD4þ T cell count dips
below 50/ml.2,3 Tumorigenesis of HIV-associated PCNSL dif-
fers from that of sporadic PCNSL in immunocompetent
hosts.4 Several potential pathogenic factors correlate with HIV-
associated PCNSL, including cytokine dysregulation, chronic
antigenic stimulation, and Epstein–Barr virus (EBV) infection.5
Each cell of HIV-associated PCNSL harbors EBV tran-
scripts.6 The EBV gene product latent membrane protein 1
(LMP1) most likely contributes to malignant transformation
by up-regulating expression of B cell lymphoma protein
(BCL)-2.7 EBVmay also help B cells, which are rarely found in
normal central nervous system (CNS) parenchyma,8,9 to enter
the CNS due to their EBV-associated activation. Furthermore,
the absence of EBV-specific CD4þ T cells in AIDS patients
with PCNSL10 implicates EBV as a critical pathogenic factor in
HIV-associated PCNSL.
Sustained immune activation is a major factor in the pro-
gressive immunodeficiency in HIV infection. Activation may
result from an increased influx of microbial components
leaking from the gut,11 theHIVNef protein,12 or opportunistic
infections.13 The influx of microbial components and oppor-
tunistic infections also contributes to immune activation by
triggering Toll-like receptors (TLRs), such as TLR 7/8.14 TLRs
belong to the family of pattern recognition receptors that
recognizes conserved motifs of microorganisms.15 Triggering
TLRs leads to complex signaling cascades, which result in
cellular activation, secretion of cytokines, and up-regulation
of MHC class molecules. The significance of TLR triggering in
HIV infection is underscored by the effects of TLR8 and 9
polymorphisms on its outcome.16,17
TLR signaling and immune activation are also linked to
EBV-associated lymphomagenesis.18 Endemic Burkitt’s lym-
phoma occurs in areas in which malaria is holoendemic. A
glycosylphosphatidylinositol anchor on the cell surface of
the malaria-causing protozoon, Plasmodium falciparum, is
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recognized by TLR2 and TLR4.19 Furthermore, the plasmodial
DNA itself exhibits a strong activation potential by triggering
TLR9.20 Overall, immune activation is thought to contribute
to the development of Burkitt’s lymphoma by stimulating the
proliferation and expansion of the pool of EBV latently
infected memory B cells, thereby increasing the risk of emer-
gence of a malignant B cell clone.18 TLR9 triggering on EBV-
infected memory B cells may also result in their terminal
differentiation into plasma cells and lytic EBV infection. Re-
lease of infectious EBV virionsmay, in turn, infect more B cells
and increase the pool of latently infected B cells. We recently
showed that triggering of TLR9 suppresses lytic EBV repli-
cation in cord blood cells infected ex vivowith EBV and in anti-
IgG-stimulated Akata Burkitt’s lymphoma cells harboring
latent EBV.21 In this way, TLR9-dependent immune activation
may contribute to EBV-associated lymphomagenesis by
suppressing lytic infection and promoting latent EBV infec-
tion with a uniquely high transformation potential. This
phenomenon may be even more pronounced in advanced
HIV infection when EBV-specific immune responses are lost.
Although only a few HIV-infected patients develop PCNSL,
TLR9 agonists may favor EBV latency and the development of
EBV-associated PCNSL.
We hypothesized that B cells from HIV-infected patients
with PCNSL respond more to TLR9 agonists than B cells from
patients without PCNSL. To test our hypothesis, we examined
the responsiveness of B cells obtained from HIV-infected pa-
tients with PCNSL, matched HIV-infected patients without
PCNSL, and healthy volunteers to a TLR9 agonist by im-
munostaining and flow cytometry. Selection of patients from
the Swiss HIV Cohort Study (SHCS) was based on docu-
mentation of PCNSL and the availability of cryopreserved
peripheral blood mononuclear cells (PBMCs) with a labora-
tory date (i.e., date of blood withdrawal) prior and as close as
possible to the date of PCNSL diagnosis. For simplicity rea-
sons, we use the term ‘‘patients with PCNSL’’ for this patient
group. Matching criteria for the HIV-infected controls (twice
as many as patients with PCNSL) were the following: (1)
gender, (2) age at the date of blood sample collection (3
years), (3) date of blood sample collection (1 year), (4) CD4þ
T cell counts (50 cells/ml), and (5) plasma HIV RNA copy
numbers. The demographics of theHIV-infected patients with
PCNSL and matched HIV-infected controls are shown in
Table 1. The profiles of CD4 count, antiretroviral therapy
(ART), and viral load (if known) over time are shown in
Supplemental Fig. 1 (see www.liebertonline.com/aid). None
of the patients was on steroids or othermedications other than
ART (when indicated). None of the patients had a microbial
infection shortly before or at the time of blood withdrawal.
We validated our assays with cryopreserved PBMCs from
HIV-negative volunteers. We observed an increase in the
percentage of CD19þ cells expressing CD25, CD69, CD80,
CD86, interleukin (IL)-6, and tumor necrosis factor (TNF)-a
(Fig. 1A) and in the mean fluorescence intensity (MFI; Fig. 1B)
in response to the TLR9 agonist CpG 2006, confirming our
approach.22 These markers were used previously to measure
the activity of TLR9 agonists.23,24
Because of the limited number of available cells, we used
stimulation of PBMCs instead of purified B cells. To validate
the use of PBMCs we isolated B cells from an HIV-negative
healthy donor and compared the up-regulation of the above-
mentioned markers/cytokines on/in B cells after stimulation
with CpG 2006 between unfractionated PBMCs and isolated B
cells. We found that up-regulation of marker/cytokine
expression was similar between PBMCs and B cells (Supple-
mental Fig. 2; see www.liebertonline.com/aid). Our experi-
mental approach is also supported by the work of Jiang et al.
who showed that the response of B cells to CpG 200625,26 is
independent of any other cell subset in PBMC.27
In HIV-infected individuals, the composition of the B cell
compartment is altered with an expansion or contraction of
one or several of the various B cell subpopulations.28 In the
present study, wewere not able to differentiate between naive
and memory B cells due to the limited number of available
cells. However, all patients in this study showed a very ad-
vanced stage of HIV disease (Table 1 and Supplemental Fig.
1). We have no reason to assume that the two groups inves-
tigated differ in their B cell composition, and, therefore, this is
unlikely to have an impact on our data.
The baseline expression levels of most of the investigated
markers/cytokines were similar in HIV-infected patients and
healthy volunteers. However, CD86 was expressed at higher
levels in HIV-infected patients without PCNSL, and the MFI
was higher in HIV-infected patients with PCNSL (data not
Table 1. Demographics of HIV-Infected Patients with PCNSL and Matched HIV-Infected Controls
HIVþ patients with PCNSL HIVþ patients without PCNSL
No. Gender
Age at
lab date
Diag date–lab
date (days)
CD4
(cells/ml)
RNA
(copies/ml)
ART at
lab date No. Gender
Age at
lab date
CD4
(cells/ml)
RNA
(copies/ml)
ART at
lab date
1 Male 35 552 111 174 Yes 1-1 Male 33 155 136 Yes
1-2 Male 37 94 122 Yes
2 Male 45 900 17 7 Yes 2-1 Male 44 24 0 Yes
2-2 NAa NA NA NA Yes
3 Male 49 204 32 880 Yes 3-1 Male 51 75 1580 Yes
3-2 Male 46 38 818 Yes
4 Male 37 48 70 Unknown No 4-1 Male 35 90 Unknown Yes
4-2 Male 40 60 Unknown No
5 Male 35 600 20 Unknown Yes 5-1 Male 32 20 Unknown Yes
5-2 Male 36 20 Unknown Yes
6 Male 48 155 30 Unknown Yes 6-1 Male 49 30 Unknown No
6-2 Male 48 40 Unknown Yes
aNA, not available.
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FIG. 1. Up-regulation of activation and costimulatory markers and of proinflammatory cytokines on/in B cells after
stimulation of PBMCs from HIV-negative donors with the TLR9 agonist CpG 2006. Cryopreserved PBMCs were rapidly
thawed and recovered in RPMI medium containing 10% FCS and 10U/ml IL-2 (¼ culture medium), centrifuged, re-
suspended in culture medium at 2.5106 cells/ml, and put into 96-well U-bottom plates at 5105 cells/well. For analysis of
activation and costimulatory markers, cells were stimulated with CpG 2006 (Microsynth GmbH, Balgach, Switzerland) at 3
(mg/ml for 24 h; control cells were not stimulated. For analysis of cytokines, cells were cultured for 18 h and then stimulated
with CpG 2006 at 3 (mg/ml for another 6 h in the presence of brefeldin A (GolgiPlug; BD Pharmingen); control cells were not
stimulated, but treated with brefeldin A. Cells were then analyzed for B cell surface marker/cytokine expression by flow
cytometry with antihuman CD19 (conjugate: FITC), CD25 (PE), CD69 (PE-Cy5), CD80 (PE), CD86 (PE-Cy5), IL-6 (PE), and
TNF-a (PE-Cy7) monoclonal antibodies (mAbs; all Abs from BD Pharmingen) on a FACSCalibur (BD Biosciences) or CyAn
ADP (Beckman Coulter) flow cytometer. Data were analyzed with FlowJo software (Tree Star). Percentage (A) and MFI (B)
are given of CD19þ cells (gated on cells defined as lymphocytes based on their forward and side scatter). Mean differences in
marker/cytokine expression between unstimulated and stimulated cells were tested for significance by the paired Student’s
t test using the program GraphPad Prism. p-values of <0.05 were considered statistically significant.
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shown). Binding of the costimulatorymarkers CD80/CD86 to
CD28 results in activation of CD4þ T cells to CTLA-4 and
leads to their inhibition.29 CTLA-4 has a much higher affinity
for CD80/CD86 than CD28. Because CTLA-4 is up-regulated
on HIV-specific CD4þ T cells in progressive disease,30 the
increased expression of CD80/86 on B cells by binding to
CTLA-4 on CD4þ T cells may contribute to the overall im-
mune dysfunction in HIV disease. Similar increases in CD86
expression in B cells from HIV viremic patients were previ-
ously reported.31
We then compared the fold-increase of marker/cytokine
expression on/in B cells after stimulation with CpG 2006,
initially without considering the pairwise matching of HIV-
infected patients (for statistical analysis see the figure leg-
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FIG. 1. (Continued).
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ends). B cells from HIV-infected patients reacted with a sim-
ilar up-regulation of CD25 and intracellular accumulation of
IL-6 as those from healthy volunteers. In contrast, fold-
increases of B cell expression were lower for CD69, CD80,
CD86, and TNF-a in HIV-infected patients than in healthy
volunteers (Fig. 2). Notably, up-regulation of CD86 is lower in
HIV-infected patients.32 The blunted up-regulation of CD86
may be explained by its higher baseline expression level,
whichmay limit themagnitude of absolute increase. Impaired
B cell reactivity is well documented in HIV infection when
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FIG. 2. Fold-increase of marker/cytokine expression in B cells from HIV-infected patients with PCNSL and those without
PCNSL compared to that of HIV-negative donors after stimulation of PBMCs with CpG 2006. PBMCs were stimulated and
analyzed as described in Fig. 1. Data are given as fold-change of percent expression (A) or MFI (B) over unstimulated. Shown
is the median with interquartile range. Differences in fold-change of marker/cytokine expression between the three groups of
donors were tested for significance by the Kruskal–Wallis test with Dunn’s multiple comparison test. P-values are given in
cases in which significant differences were found (i.e., p-values of <0.05).
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assessing vaccine responses.33–35 Notably, in patients with
PCNSL the fold-increases were even less pronounced for
CD69 and TNF-a than in patients without PCNSL (see below).
Similar to our data, B cell receptor/CD40 stimulation also
results in a reduced up-regulation of CD25, CD80, and CD86
in HIV viremic patients as compared to HIV-negative vol-
unteers.31 Thus, B cells in HIV infection appear to have a
generally reduced reactivity, independent of the stimuli.
The key interest of our work was to compare the reactivity
to TLR9 triggering of B cells from HIV-infected patients with
PCNSL to those from HIV-infected patients without PCNSL.
We thus reanalyzed the data, now using paired Student’s
t test, considering the pairwise matching. At baseline, we
observed significantly higher levels of IL-6 expression (in
percentage of cells and MFI) and CD86 MFI and significantly
lower levels of TNF-a expression (in percentage of cells and
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FIG. 2. (Continued).
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MFI) by B cells from the HIV-infected patients with PCNSL as
compared to the matched controls (Fig. 3). CD80 expression
(MFI) at baseline was also increased, but this difference did
not reach statistical significance.
As noted above, the increased expression of CD80/CD86
may result in an increased binding of B to T cells via the
interaction of these markers with CTLA-4, contributing to
a decreased T cell reactivity and potentially to a decreased
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FIG. 3. Comparison of baseline expression of B cell markers between HIV-infected patients with PCNSL and matched
controls. PBMCs were cultured without stimulation and analyzed as described in Fig. 1. Percentage (A) and MFI (B) are given
of CD19þ cells. Mean differences in marker/cytokine expression between HIV-infected patients with PCNSL and matched
controls were tested for significance by the paired Student’s t test. p-values are given in cases with significant (or nearly
significant) differences (i.e., p-values of <0.05).
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EBV-specific T cell response. The obvious lack of EBV-specific
CD4þ T cells10 together with the increased expression of
CD80/CD86 may represent a unique risk profile for those
HIV-infected patients with PCNSL. Studies performed in the
1990s showed that elevated serum/plasma IL-6 levels pre-
ceded the diagnosis of AIDS-related lymphoma.36,37 Fur-
thermore, the higher IL-6 expression levels at baseline is
similar to a report linking increased IL-6 levels to the risk for
Hodgkin’s lymphoma,38 another EBV-associated neoplasia.
Thus, IL-6may be implicated in the etiology of PCNSL. TNF-a
induces IL-639; thus, increases of IL-6 should parallel increases
in TNF-a. However, this was not the case: patients with
PCNSL showed reduced expression of TNF-a. The signifi-
cance of this observation is unknown. We cannot exclude the
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possibility that there is an increased production of TNF-a in
other, non-B cell subsets such as T cells, and that this may
compensate for the lower TNF-a production in B cells.
After treatment with CpG 2006, we observed that B cells
from patients with PCNSL showed less pronounced up-reg-
ulation of CD80 expression and TNF-a production than B cells
from matched controls (Fig. 4). Because there was a tendency
toward increased baseline levels of CD80 in HIV-infected
patients with PCNSL, the lack of its further increase subse-
quent to stimulation with CpG 2006 speaks in favor of a
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FIG. 4. Comparison of responsiveness of B cells to TLR9 stimulation between HIV-infected patients with PCNSL and
matched controls. PBMCs were stimulated and analyzed as described in Fig. 1. Data are given as fold-change of percent
expression (A) or MFI (B) over unstimulated. Mean differences in fold-change of marker/cytokine expression between HIV-
infected patient with PCNSL and matched controls were tested for significance by the paired Student’s t test. p-values are
given in cases in which significant differences were found (i.e., p-values of <0.05).
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threshold of maximal expression. This cannot explain the re-
duced TNF-a response since its production was decreased at
baseline in B cells of patients with PCNSL compared to the
matched controls, suggesting a specific disturbance resulting
in impaired TNF-a production in patients with PCNSL.
In conclusion, we found that B cells from HIV-infected
patients with PCNSL display an activated phenotype (in-
creased IL-6 and CD86 expression at baseline) and have a
blunted TNF-a response to TLR9 triggering. The enhanced
baseline expression of IL-6 might be important in the patho-
genesis of PCNSL in HIV-infected patients since increased
IL-6 expression is linked to EBV-associated Hodgkin’s lym-
phoma. The impaired TNF-a response despite a decreased
baseline expression is intriguing and warrants further inves-
tigation. A study with a larger sample size of HIV-infected
patients with PCNSL is not realistic with most HIV-infected
patients being under ART and because of the very low inci-
dence of PCNSL. However, it would be of great interest to
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examine whether B cells of patients with other forms of EBV-
associated lymphoma and in particular with endemic Bur-
kitt’s lymphoma have aberrant signaling responses to TLR9
triggering.
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